Analysts Expect Voyager Therapeutics (VYGR) Will Post Earnings of -$0.62 Per Share

Wall Street brokerages expect that Voyager Therapeutics (NASDAQ:VYGR) will post earnings per share (EPS) of ($0.62) for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Voyager Therapeutics’ earnings, with estimates ranging from ($0.76) to ($0.47). Voyager Therapeutics posted earnings of ($0.73) per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 15.1%. The business is expected to issue its next quarterly earnings results on Tuesday, August 14th.

According to Zacks, analysts expect that Voyager Therapeutics will report full year earnings of ($2.71) per share for the current fiscal year, with EPS estimates ranging from ($3.26) to ($2.10). For the next year, analysts anticipate that the business will report earnings of ($3.12) per share, with EPS estimates ranging from ($4.38) to ($2.38). Zacks’ earnings per share calculations are a mean average based on a survey of analysts that follow Voyager Therapeutics.

Voyager Therapeutics (NASDAQ:VYGR) last released its earnings results on Thursday, May 10th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.11) by ($0.52). The business had revenue of $0.94 million for the quarter, compared to analyst estimates of $4.00 million. Voyager Therapeutics had a negative return on equity of 69.92% and a negative net margin of 768.99%.

A number of equities research analysts have issued reports on VYGR shares. Zacks Investment Research upgraded shares of Voyager Therapeutics from a “hold” rating to a “buy” rating and set a $26.00 target price on the stock in a report on Friday, March 16th. BidaskClub lowered shares of Voyager Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, April 19th. Wedbush increased their target price on shares of Voyager Therapeutics from $22.00 to $29.00 and gave the stock an “outperform” rating in a report on Wednesday, February 21st. Canaccord Genuity set a $35.00 target price on shares of Voyager Therapeutics and gave the stock a “buy” rating in a report on Wednesday, March 14th. Finally, BTIG Research reiterated a “buy” rating and set a $32.00 target price on shares of Voyager Therapeutics in a report on Sunday, March 11th. Three research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. Voyager Therapeutics has a consensus rating of “Buy” and an average target price of $29.73.

In other news, CFO Jane Henderson sold 17,316 shares of the firm’s stock in a transaction on Monday, March 19th. The shares were sold at an average price of $22.11, for a total value of $382,856.76. Following the sale, the chief financial officer now directly owns 15,416 shares in the company, valued at approximately $340,847.76. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Bernard Ravina sold 2,451 shares of the firm’s stock in a transaction on Monday, March 12th. The shares were sold at an average price of $25.16, for a total transaction of $61,667.16. The disclosure for this sale can be found here. Insiders sold a total of 64,457 shares of company stock worth $1,529,552 over the last 90 days. Company insiders own 33.60% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in VYGR. BlackRock Inc. raised its holdings in shares of Voyager Therapeutics by 73.9% in the 4th quarter. BlackRock Inc. now owns 1,210,763 shares of the company’s stock valued at $20,099,000 after purchasing an additional 514,345 shares in the last quarter. Farallon Capital Management LLC raised its holdings in shares of Voyager Therapeutics by 290.5% in the 4th quarter. Farallon Capital Management LLC now owns 654,812 shares of the company’s stock valued at $10,870,000 after purchasing an additional 487,147 shares in the last quarter. BB Biotech AG raised its holdings in shares of Voyager Therapeutics by 29.4% in the 1st quarter. BB Biotech AG now owns 1,992,641 shares of the company’s stock valued at $37,442,000 after purchasing an additional 453,121 shares in the last quarter. Millennium Management LLC raised its stake in Voyager Therapeutics by 124.0% during the 1st quarter. Millennium Management LLC now owns 618,021 shares of the company’s stock worth $11,613,000 after acquiring an additional 342,148 shares in the last quarter. Finally, AXA acquired a new stake in Voyager Therapeutics during the 4th quarter worth $5,591,000. Institutional investors and hedge funds own 84.03% of the company’s stock.

Voyager Therapeutics opened at $18.58 on Friday, MarketBeat Ratings reports. The company has a market cap of $606.34 million, a price-to-earnings ratio of -7.04 and a beta of 2.98. Voyager Therapeutics has a 52-week low of $8.10 and a 52-week high of $31.91.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trials for the treatment of advanced Parkinson's disease.

Get a free copy of the Zacks research report on Voyager Therapeutics (VYGR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply